Across TCGA pan-cancer cohorts, EFNA1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EFNA1 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher EFNA1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EFNA1 expression acts as an unfavorable survival marker.
COAD and BLCA are the cancer types where EFNA1 Mutation most reproducibly stratifies survival.